Geron Corporation (GERN) is a Biotechnology company in the Healthcare sector, currently trading at $1.69. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is GERN = $6 (+248.5% upside).
Valuation: GERN trades at a trailing Price-to-Earnings (P/E) of -13.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.08.
Financials: revenue is $184M, +10821.8%/yr average growth. Net income is $86M (loss), growing at +8.5%/yr. Net profit margin is -46.7% (negative). Gross margin is 97.4% (+143 pp trend).
Balance sheet: total debt is $252M against $226M equity (Debt-to-Equity (D/E) ratio 1.11, moderate). Current ratio is 4.66 (strong liquidity). Debt-to-assets is 44.1%. Total assets: $571M.
Analyst outlook: 17 / 22 analysts rate GERN as buy (77%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 83/100 (Pass), Past 0/100 (Fail), Health 50/100 (Partial), Moat 70/100 (Pass), Future 85/100 (Pass), Income 10/100 (Fail).
